{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Triple-negative+Breast+Cancer&page=2",
    "query": {
      "condition": "Advanced Triple-negative Breast Cancer",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Triple-negative+Breast+Cancer&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T09:46:36.472Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07067138",
      "title": "A Synthetic Lethality-Focused Algorithm to Identify Therapeutic Options in Advanced Metastatic Breast Cancer (SYNTHESIS-Breast)",
      "overall_status": "SUSPENDED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Breast Cancer",
        "Breast Carcinoma",
        "Cancer of the Breast",
        "Malignant Neoplasm of Breast"
      ],
      "interventions": [
        {
          "name": "Expression Networks for highLIGHting Tumor vulnerabilities (ENLIGHT)",
          "type": "DEVICE"
        },
        {
          "name": "TruSight(R) Oncology 500",
          "type": "DEVICE"
        },
        {
          "name": "TruSeq Matched Tumor Normal Whole Exome Sequencing Assay",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 175,
      "start_date": "2026-02-23",
      "completion_date": "2029-08-04",
      "has_results": false,
      "last_update_posted_date": "2026-05-18",
      "last_synced_at": "2026-05-22T09:46:36.472Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07067138"
    },
    {
      "nct_id": "NCT01337765",
      "title": "Safety, Pharmacokinetics and Pharmacodynamics of BEZ235 Plus MEK162 in Selected Advanced Solid Tumor Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Unspecified Adult Solid Tumor, Protocol Specific",
        "Solid Tumor"
      ],
      "interventions": [
        {
          "name": "BEZ235 + MEK162",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 29,
      "start_date": "2011-07-08",
      "completion_date": "2013-03-22",
      "has_results": false,
      "last_update_posted_date": "2020-10-09",
      "last_synced_at": "2026-05-22T09:46:36.472Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts • Houston, Texas",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01337765"
    },
    {
      "nct_id": "NCT02834247",
      "title": "A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Triple-Negative Breast Neoplasms",
        "Carcinoma, Non-Small-Cell Lung",
        "Head and Neck Carcinoma, Squamous Cell",
        "Advanced Solid Tumors"
      ],
      "interventions": [
        {
          "name": "TAK-659",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Calithera Biosciences, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 41,
      "start_date": "2016-08-12",
      "completion_date": "2018-11-30",
      "has_results": true,
      "last_update_posted_date": "2023-02-08",
      "last_synced_at": "2026-05-22T09:46:36.472Z",
      "location_count": 9,
      "location_summary": "La Jolla, California • Atlanta, Georgia • Boston, Massachusetts + 6 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02834247"
    },
    {
      "nct_id": "NCT05382299",
      "title": "Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Triple Negative Breast Cancer",
        "PD-L1 Negative"
      ],
      "interventions": [
        {
          "name": "Sacituzumab Govitecan-hziy",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "nab-Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 623,
      "start_date": "2022-07-20",
      "completion_date": "2028-07",
      "has_results": false,
      "last_update_posted_date": "2026-04-06",
      "last_synced_at": "2026-05-22T09:46:36.472Z",
      "location_count": 130,
      "location_summary": "Tucson, Arizona • Burbank, California • La Jolla, California + 92 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Burbank",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05382299"
    },
    {
      "nct_id": "NCT03667716",
      "title": "COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Cancer",
        "Ovarian Cancer",
        "Breast Cancer",
        "Lung Cancer",
        "Endometrial Cancer",
        "Ovarian Neoplasm",
        "Triple Negative Breast Cancer",
        "Lung Neoplasm",
        "Neoplasm Malignant",
        "Colo-rectal Cancer"
      ],
      "interventions": [
        {
          "name": "COM701",
          "type": "DRUG"
        },
        {
          "name": "COM701 with Opdivo (Nivolumab).",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Compugen Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 121,
      "start_date": "2018-09-06",
      "completion_date": "2024-01-30",
      "has_results": false,
      "last_update_posted_date": "2025-01-17",
      "last_synced_at": "2026-05-22T09:46:36.472Z",
      "location_count": 11,
      "location_summary": "Los Angeles, California • Sarasota, Florida • Chicago, Illinois + 8 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03667716"
    },
    {
      "nct_id": "NCT02038699",
      "title": "A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Glioblastoma",
        "Advanced Colorectal Cancer",
        "Advanced Triple-negative Breast Cancer",
        "Advanced Non-small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "ONC201",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Jazz Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2014-01",
      "completion_date": "2016-12",
      "has_results": false,
      "last_update_posted_date": "2021-04-30",
      "last_synced_at": "2026-05-22T09:46:36.472Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02038699"
    },
    {
      "nct_id": "NCT04726332",
      "title": "Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neoplasm Malignant",
        "Epithelial Ovarian Cancer",
        "Triple Negative Breast Cancer",
        "Hormone Receptor Positive Breast Carcinoma",
        "Metastatic Castration-resistant Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "XL102",
          "type": "DRUG"
        },
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        },
        {
          "name": "Abiraterone",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Exelixis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 52,
      "start_date": "2021-02-10",
      "completion_date": "2024-05-02",
      "has_results": false,
      "last_update_posted_date": "2024-05-14",
      "last_synced_at": "2026-05-22T09:46:36.472Z",
      "location_count": 5,
      "location_summary": "Atlanta, Georgia • Boston, Massachusetts • Dallas, Texas + 2 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04726332"
    },
    {
      "nct_id": "NCT04244552",
      "title": "A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer",
        "Colorectal Cancer",
        "Ovarian Cancer",
        "Non-Small Cell Lung Cancer",
        "Acral Lentiginous Melanoma",
        "Head and Neck Squamous Cell Carcinoma",
        "Hepatocellular Carcinoma",
        "Esophageal Squamous Cell Carcinoma",
        "Urothelial Carcinoma",
        "DMMR Colorectal Cancer",
        "MSI-H Colorectal Cancer",
        "Melanoma",
        "Platinum-Resistant Primary Peritoneal Carcinoma",
        "Platinum-Resistant Fallopian Tube Carcinoma",
        "Platinum-Resistant Epithelial Ovarian Cancer",
        "Triple Negative Breast Cancer"
      ],
      "interventions": [
        {
          "name": "ATRC-101",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pegylated liposomal doxorubicin (PLD)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Atreca, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 87,
      "start_date": "2020-02-11",
      "completion_date": "2023-11-01",
      "has_results": false,
      "last_update_posted_date": "2023-12-29",
      "last_synced_at": "2026-05-22T09:46:36.472Z",
      "location_count": 19,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Duarte, California + 15 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04244552"
    },
    {
      "nct_id": "NCT06324240",
      "title": "Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Anatomic Stage I Breast Cancer AJCC v8",
        "Anatomic Stage IA Breast Cancer AJCC v8",
        "Anatomic Stage IB Breast Cancer AJCC v8",
        "Anatomic Stage II Breast Cancer AJCC v8",
        "Anatomic Stage IIA Breast Cancer AJCC v8",
        "Anatomic Stage IIB Breast Cancer AJCC v8",
        "Anatomic Stage III Breast Cancer AJCC v8",
        "Anatomic Stage IIIA Breast Cancer AJCC v8",
        "Anatomic Stage IIIB Breast Cancer AJCC v8",
        "Anatomic Stage IIIC Breast Cancer AJCC v8",
        "Anatomic Stage IV Breast Cancer AJCC v8",
        "Early Stage Triple-Negative Breast Carcinoma",
        "Locally Advanced Triple-Negative Breast Carcinoma",
        "Metastatic Triple-Negative Breast Carcinoma",
        "Prognostic Stage I Breast Cancer AJCC v8",
        "Prognostic Stage IA Breast Cancer AJCC v8",
        "Prognostic Stage IB Breast Cancer AJCC v8",
        "Prognostic Stage II Breast Cancer AJCC v8",
        "Prognostic Stage IIA Breast Cancer AJCC v8",
        "Prognostic Stage IIB Breast Cancer AJCC v8",
        "Prognostic Stage III Breast Cancer AJCC v8",
        "Prognostic Stage IIIA Breast Cancer AJCC v8",
        "Prognostic Stage IIIB Breast Cancer AJCC v8",
        "Prognostic Stage IIIC Breast Cancer AJCC v8",
        "Prognostic Stage IV Breast Cancer AJCC v8",
        "Recurrent Breast Carcinoma",
        "Unresectable Triple-Negative Breast Carcinoma"
      ],
      "interventions": [
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Vaccine Therapy",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2025-12-02",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-01-26",
      "last_synced_at": "2026-05-22T09:46:36.472Z",
      "location_count": 4,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06324240"
    },
    {
      "nct_id": "NCT04099277",
      "title": "A Study of LY3435151 in Participants With Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumor",
        "Triple-negative Breast Cancer",
        "Gastric Adenocarcinoma",
        "Head and Neck Squamous Cell Carcinoma",
        "Cervical Carcinoma",
        "High Grade Serous Ovarian Carcinoma",
        "Hepatocellular Carcinoma",
        "Undifferentiated Pleomorphic Sarcoma",
        "Leiomyosarcoma"
      ],
      "interventions": [
        {
          "name": "LY3435151",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2019-10-28",
      "completion_date": "2020-03-05",
      "has_results": true,
      "last_update_posted_date": "2021-08-31",
      "last_synced_at": "2026-05-22T09:46:36.472Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04099277"
    }
  ]
}